Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10533MR)

This product GTTS-WQ10533MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10533MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13221MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ15839MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ6057MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ5810MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ7474MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ3044MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ15368MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ68MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW